EXPRS2 — ExpreS2ion Biotech Holding AB Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapMomentum Trap

Annual income statement for ExpreS2ion Biotech Holding AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

	R2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	SAS	SAS	SAS	SAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	13.8	15.3	13.7	6.15	8.8
Cost of Revenue
Gross Profit	10.4	9.16	2.7	-13.8	-9.66
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	32.5	46.7	62.1	134	115
Operating Profit	-18.7	-31.4	-48.4	-128	-106
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Net Income Before Taxes	-19.6	-34.9	-47.5	-127	-105
Provision for Income Taxes
Net Income After Taxes	-17.3	-31.7	-43.9	-119	-96
Net Income Before Extraordinary Items
Net Income	-17.3	-31.7	-43.9	-119	-96
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-17.3	-31.7	-43.9	-119	-96
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1.06	-1.02	-1.27	-3.14	-1.87
Dividends per Share